NCT03096340View on ClinicalTrials.gov

Safety and Pharmacokinetic Study of IT-141 in Monotherapy in Patients With Advanced Cancer

PHASE1TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

March 23, 2017

Primary Completion Date

August 22, 2018

Study Completion Date

November 26, 2019

Conditions
CancerNeoplasmsTumorsRefractory Solid TumorsRecurrent Solid Tumors
Interventions
DRUG

IT-141

Escalating doses administered in mg/m2, IV (in the vein) on days 1 and 15 of each 28 day cycle until progression or unacceptable toxicity develops.

Trial Locations (2)

75230

Mary Crowley Cancer Research Centers - Medical City, Dallas

98109

Seattle Cancer Care Alliance, Seattle

Sponsors
All Listed Sponsors
lead

Intezyne Technologies, Inc.

INDUSTRY